We and others have demonstrated that Mcl-1 plays an important role in the antileukemic activity of the Bcl-2-selective inhibitor ABT-199 in AML and other blood cancer cells [12, 16–18]. Here, MCL1 is linked to hematopoietic and lymphoid system neoplasm.